Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Emerging Approaches Offer Hope in Heavily Pretreated Myeloma

August 7th 2018

Suman Kambhampati, MD, discusses some of the latest developments in the treatment of patients with relapsed/refractory multiple myeloma.

bb2121 Continues to Show Potential in Multiple Myeloma

August 2nd 2018

Noopur Raje, MD, discusses the updated results from the CRB-401 trial and next steps with bb2121 in multiple myeloma.

Dr. Kambhampati on Updates in Myeloma from the 2018 ASCO Annual Meeting

August 2nd 2018

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses updates in myeloma from the 2018 ASCO Annual Meeting.

EU Panel Backs Frontline Daratumumab/VMP Combo for Multiple Myeloma

July 27th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of daratumumab in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Dr. Holstein Discusses Induction Therapy for Multiple Myeloma

July 23rd 2018

Sarah Holstein, MD, PhD, associate professor, University of Nebraska Medical Center, discusses induction therapy for the treatment of patients with multiple myeloma.

Dr. Lonial Discusses Emerging Agents in Relapsed/Refractory Myeloma

July 20th 2018

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses emerging agents in relapsed/refractory multiple myeloma.

Lonial Lays Out Optimal Sequence Strategies for Relapsed/Refractory Myeloma

July 20th 2018

Sagar Lonial, MD, discusses optimal sequencing techniques for patients with relapsed/refractory myeloma.

Immunotherapy Treatment Options Continue to Grow in Relapsed/Refractory Multiple Myeloma

July 20th 2018

Sham Mailankody, MBBS, discusses current treatment options and shifting preferences, especially toward triplet combinations, as well as emerging immunotherapy treatment options in multiple myeloma.

The Future of Myeloma Induction May Be Quadruplets

July 19th 2018

Sarah Holstein, MD, PhD, discusses new approaches to induction therapy for patients with myeloma.

Selinexor FDA Submission Started for Multiple Myeloma

July 18th 2018

A rolling submission of an FDA new drug application (NDA) has been submitted for selinexor for the treatment of patients with penta-refractory multiple myeloma.

Multiple Myeloma: Closing Considerations for Treatment

July 18th 2018

Addressing Treatment of Myeloma-Related Comorbidity

July 18th 2018

Venetoclax: Potential Use in Multiple Myeloma

July 18th 2018

Considering Selinexor in Penta-Refractory Myeloma

July 18th 2018

Optimizing the Use of Anti-BCMA Therapy in MM

July 18th 2018

The Promise of Anti-BCMA CAR T-Cell Therapy in MM

July 18th 2018

Evaluating MRD's Role in Multiple Myeloma

July 18th 2018

Using MRD to Determine Cure in Multiple Myeloma

July 18th 2018

Sequencing Through Multiple Lines of Therapy

July 18th 2018

Selecting a Proteasome Inhibitor in Multiple Myeloma

July 18th 2018